Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details)

v3.26.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details)
1 Months Ended 3 Months Ended
Sep. 30, 2019
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 8,000,000    
Long-term royalty and commercial payment receivables under the cost recovery method     $ 55,886,000 $ 55,888,000
Short-term royalty and commercial payment receivables under the cost recovery method     0 0
Palobiofarma | Royalty Purchase Agreement        
Agreements        
Number of drug candidates 6      
Payments of consideration under RPAs, AAAs and CPPAs $ 10,000,000      
Long-term royalty and commercial payment receivables under the cost recovery method $ 10,000,000      
Short-term royalty and commercial payment receivables under the cost recovery method     0  
Allowance for credit losses     $ 0 $ 0